-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-published Nature Aging
In AD patients confirmed by disease biomarkers, AADvac1 showed efficacy signals, which significantly delayed the decline of clinical and functional indicators in patients
Neurofibrillary tangles (NFT) composed of pathological tau protein aggregation is one of the hallmarks of AD patients’ brains
AADvac1 is a tau protein vaccine designed to target the production and spread of pathological tau protein
In a 24-month randomized double-blind, placebo-controlled phase 2 clinical trial, AADvac1 reached the primary endpoint of the trial, showing good safety and tolerability
In addition, AADvac1 significantly reduced the accumulation of nerve fiber light chain (NfL)
In the subgroup of AD patients confirmed by AD biomarker amyloid deposition and tau protein aggregation, compared with placebo, AADvac1 delayed the clinical decline detected by CDR-SB by 27% (p=0.
Note: The original text has been deleted
Reference materials:
Reference materials:[1] Nature Aging publishes phase II results for AADvac1, a first-in-man Alzheimer's tau vaccine developed by Axon Neuroscience.
[1] Nature Aging publishes phase II results for AADvac1, a first-in-man Alzheimer's tau vaccine developed by Axon Neuroscience.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number